Comprehensive Stock Comparison
Compare Aurinia Pharmaceuticals Inc. (AUPH) vs RAPT Therapeutics, Inc. (RAPT) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Stability / Safety | AUPH | Beta 0.64 vs RAPT's 0.78 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | RAPT | +5.4% vs AUPH's +78.2% |
| Efficiency (ROA) | AUPH | 38.2% ROA vs RAPT's -63.7%, ROIC 16.6% vs -155.7% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Aurinia Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes therapies for autoimmune diseases with unmet medical needs. It generates revenue primarily from sales of LUPKYNIS — its FDA-approved oral treatment for lupus nephritis — with additional income from its collaboration and licensing agreement with Otsuka Pharmaceutical. The company's key advantage is its first-mover position in the oral treatment space for lupus nephritis, a serious kidney complication of systemic lupus erythematosus where treatment options have been limited.
RAPT Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule therapies for cancer and inflammatory diseases. It generates no revenue yet as it's in clinical trials, with future income dependent on potential drug approvals and commercialization. The company's competitive advantage lies in its targeted CCR4 antagonist platform that selectively inhibits immune cell migration to diseased tissues.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
AUPH leads in 3 of 6 categories (Financial Metrics, Profitability & Efficiency). RAPT leads in 1 (Valuation Metrics). 1 tied.
Financial Metrics (TTM)
AUPH and RAPT operate at a comparable scale, with $283M and $0 in trailing revenue.
| Metric | AUPHAurinia Pharmaceu… | RAPTRAPT Therapeutics… |
|---|---|---|
| RevenueTrailing 12 months | $283M | $0 |
| EBITDAEarnings before interest/tax | $105M | -$112M |
| Net IncomeAfter-tax profit | $287M | -$106M |
| Free Cash FlowCash after capex | $135M | -$87M |
| Gross MarginGross profit ÷ Revenue | +88.5% | — |
| Operating MarginEBIT ÷ Revenue | +37.1% | — |
| Net MarginNet income ÷ Revenue | +101.5% | — |
| FCF MarginFCF ÷ Revenue | +47.8% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +28.8% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +152.0% | +82.9% |
Valuation Metrics
| Metric | AUPHAurinia Pharmaceu… | RAPTRAPT Therapeutics… |
|---|---|---|
| Market CapShares × price | $1.9B | $7.7B |
| Enterprise ValueMkt cap + debt − cash | $1.9B | $7.5B |
| Trailing P/EPrice ÷ TTM EPS | 6.85x | -2.27x |
| Forward P/EPrice ÷ next-FY EPS est. | 16.87x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 17.82x | — |
| Price / SalesMarket cap ÷ Revenue | 6.62x | — |
| Price / BookPrice ÷ Book value/share | 3.38x | 1.56x |
| Price / FCFMarket cap ÷ FCF | 13.85x | — |
Profitability & Efficiency
AUPH delivers a 49.4% return on equity — every $100 of shareholder capital generates $49 in annual profit, vs $-70 for RAPT. RAPT carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to AUPH's 0.13x. On the Piotroski fundamental quality scale (0–9), AUPH scores 7/9 vs RAPT's 2/9, reflecting strong financial health.
| Metric | AUPHAurinia Pharmaceu… | RAPTRAPT Therapeutics… |
|---|---|---|
| ROE (TTM)Return on equity | +49.4% | -69.5% |
| ROA (TTM)Return on assets | +38.2% | -63.7% |
| ROICReturn on invested capital | +16.6% | -155.7% |
| ROCEReturn on capital employed | +18.9% | -79.3% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 2 |
| Debt / EquityFinancial leverage | 0.13x | 0.02x |
| Net DebtTotal debt minus cash | -$5M | -$165M |
| Cash & Equiv.Liquid assets | $80M | $170M |
| Total DebtShort + long-term debt | $75M | $4M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
Total Returns (with DRIP)
A $10,000 investment in AUPH five years ago would be worth $9,786 today (with dividends reinvested), compared to $3,869 for RAPT. Over the past 12 months, RAPT leads with a +535.7% total return vs AUPH's +78.2%. The 3-year compound annual growth rate (CAGR) favors AUPH at 15.9% vs RAPT's -37.3% — a key indicator of consistent wealth creation.
| Metric | AUPHAurinia Pharmaceu… | RAPTRAPT Therapeutics… |
|---|---|---|
| YTD ReturnYear-to-date | -7.7% | +82.0% |
| 1-Year ReturnPast 12 months | +78.2% | +535.7% |
| 3-Year ReturnCumulative with dividends | +55.9% | -75.4% |
| 5-Year ReturnCumulative with dividends | -2.1% | -61.3% |
| 10-Year ReturnCumulative with dividends | +497.9% | -44.3% |
| CAGR (3Y)Annualised 3-year return | +15.9% | -37.3% |
Risk & Volatility
AUPH is the less volatile stock with a 0.64 beta — it tends to amplify market swings less than RAPT's 0.78 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RAPT currently trades 100.0% from its 52-week high vs AUPH's 85.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | AUPHAurinia Pharmaceu… | RAPTRAPT Therapeutics… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.64x | 0.78x |
| 52-Week HighHighest price in past year | $16.54 | $57.99 |
| 52-Week LowLowest price in past year | $6.83 | $5.67 |
| % of 52W HighCurrent price vs 52-week peak | +85.7% | +100.0% |
| RSI (14)Momentum oscillator 0–100 | 37.4 | 79.2 |
| Avg Volume (50D)Average daily shares traded | 782K | 2.8M |
Analyst Outlook
Wall Street rates AUPH as "Buy" and RAPT as "Hold". Consensus price targets imply 9.4% upside for AUPH (target: $16) vs 3.5% for RAPT (target: $60).
| Metric | AUPHAurinia Pharmaceu… | RAPTRAPT Therapeutics… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold |
| Price TargetConsensus 12-month target | $15.50 | $60.00 |
| # AnalystsCovering analysts | 14 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +5.2% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Feb 20 | Feb 26 | Change |
|---|---|---|---|
| Aurinia Pharmaceuti… (AUPH) | 100 | 86.97 | -13.0% |
| RAPT Therapeutics, … (RAPT) | 100 | 36.47 | -63.5% |
Aurinia Pharmaceuti… (AUPH) returned -2% over 5 years vs RAPT Therapeutics, … (RAPT)'s -61%.
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Aurinia Pharmaceuti… (AUPH) | $173000.00 | $283M | +163515.6% |
| RAPT Therapeutics, … (RAPT) | $0.00 | $0.00 | — |
Aurinia Pharmaceuticals Inc.'s revenue grew from $0M (2016) to $283M (2025) — a 127.6% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Aurinia Pharmaceuti… (AUPH) | -134.7% | 101.5% | +175.4% |
| RAPT Therapeutics, … (RAPT) | -10.5% | -54.9% | -423.4% |
Aurinia Pharmaceuticals Inc.'s net margin went from -135% (2016) to 101% (2025).
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Aurinia Pharmaceuti… (AUPH) | -0.66 | 2.07 | +413.6% |
| RAPT Therapeutics, … (RAPT) | -10.95 | -25.49 | -132.9% |
Aurinia Pharmaceuticals Inc.'s EPS grew from $-0.66 (2016) to $2.07 (2025).
Chart 5Free Cash Flow — 5 Years
Aurinia Pharmaceuticals Inc. generated $135M FCF in 2025 (+185% vs 2021). RAPT Therapeutics, Inc. generated $-83M FCF in 2024 (-35% vs 2021).
AUPH vs RAPT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is AUPH or RAPT a better buy right now?
Aurinia Pharmaceuticals Inc. (AUPH) offers the better valuation at 6.8x trailing P/E (16.9x forward), making it the more compelling value choice. Analysts rate Aurinia Pharmaceuticals Inc. (AUPH) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — AUPH or RAPT?
Over the past 5 years, Aurinia Pharmaceuticals Inc. (AUPH) delivered a total return of -2.1%, compared to -61.3% for RAPT Therapeutics, Inc. (RAPT). A $10,000 investment in AUPH five years ago would be worth approximately $10K today (assuming dividends reinvested). Over 10 years, the gap is even starker: AUPH returned +497.9% versus RAPT's -44.3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — AUPH or RAPT?
By beta (market sensitivity over 5 years), Aurinia Pharmaceuticals Inc. (AUPH) is the lower-risk stock at 0.64β versus RAPT Therapeutics, Inc.'s 0.78β — meaning RAPT is approximately 22% more volatile than AUPH relative to the S&P 500. On balance sheet safety, RAPT Therapeutics, Inc. (RAPT) carries a lower debt/equity ratio of 2% versus 13% for Aurinia Pharmaceuticals Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — AUPH or RAPT?
Aurinia Pharmaceuticals Inc. (AUPH) is the more profitable company, earning 101.5% net margin versus 0.0% for RAPT Therapeutics, Inc. — meaning it keeps 101.5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AUPH leads at 37.1% versus 0.0% for RAPT. At the gross margin level — before operating expenses — AUPH leads at 88.5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is AUPH or RAPT more undervalued right now?
Analyst consensus price targets imply the most upside for AUPH: 9.4% to $15.50.
06Which pays a better dividend — AUPH or RAPT?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is AUPH or RAPT better for a retirement portfolio?
For long-horizon retirement investors, Aurinia Pharmaceuticals Inc. (AUPH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.64), +497.9% 10Y return). Both have compounded well over 10 years (AUPH: +497.9%, RAPT: -44.3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between AUPH and RAPT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: AUPH is a small-cap deep-value stock; RAPT is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.